ST6Gal-I sialyltransferase confers cisplatin resistance in ovarian tumor cells

Journal of Ovarian Research

Volumn 6, Issue 1, 2013, Pages

  Schultz, Matthew J ^a   Swindall, Amanda F ^a   Wright, John W ^a   Sztul, Elizabeth S ^a   Landen, Charles N ^b   Bellis, Susan L ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Apoptosis; Cisplatin; Glycosylation; Ovarian cancer; Sialic acid

Indexed keywords

CASPASE 3; CISPLATIN; SHORT HAIRPIN RNA; SIALYLTRANSFERASE; ST6GAL I PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL POPULATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIALYLATION; UPREGULATION;

EID: 84875929161     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-6-25     Document Type: Article

References (50)

1. Genetically altered mice with different sialyltransferase deficiencies show tissue-specific alterations in sialylation and sialic acid 9-O-acetylation. Martin LT, Marth JD, Varki A, Varki NM, J Biol Chem 2002 277 32930 32938 10.1074/jbc.M203362200 12068010 (Pubitemid 34987555)
2. Immune regulation by the ST6Gal sialyltransferase. Hennet T, Chui D, Paulson JC, Marth JD, Proc Natl Acad Sci U S A 1998 95 4504 4509 10.1073/pnas.95.8.4504 9539767 (Pubitemid 28207942)
3. Regulation of the metastatic cell phenotype by sialylated glycans. Schultz MJ, Swindall AF, Bellis SL, Cancer Metastasis Rev 2012 31 501 518 10.1007/s10555-012-9359-7 22699311
4. Emerging role of alpha2,6-sialic acid as a negative regulator of galectin binding and function. Zhuo Y, Bellis SL, J Biol Chem 2010 286 5935 5941 21173156
5. Glycosylation, galectins and cellular signaling. Boscher C, Dennis JW, Nabi IR, Curr Opin Cell Biol 2011 23 383 392 10.1016/j.ceb.2011.05.001 21616652
6. T-cell growth, cell surface organization, and the galectin-glycoprotein lattice. Grigorian A, Torossian S, Demetriou M, Immunol Rev 2009 230 232 246 10.1111/j.1600-065X.2009.00796.x 19594640
7. Galectin-glycan lattices regulate cell-surface glycoprotein organization and signalling. Garner OB, Baum LG, Biochem Soc Trans 2008 36 1472 1477 10.1042/BST0361472 19021578
8. Sialylation of the Fas death receptor by ST6Gal-I provides protection against Fas-mediated apoptosis in colon carcinoma cells. Swindall AF, Bellis SL, J Biol Chem 2011 286 22982 22990 10.1074/jbc.M110.211375 21550977
9. Ras oncogene directs expression of a differentially sialylated, functionally altered beta1 integrin. Seales EC, Jurado GA, Singhal A, Bellis SL, Oncogene 2003 22 7137 7145 10.1038/sj.onc.1206834 14562042 (Pubitemid 37378546)
10. Ras oncogene induces beta-galactoside alpha2,6-sialyltransferase (ST6Gal I) via a RalGEF-mediated signal to its housekeeping promoter. Dalziel M, Dall'Olio F, Mungul A, Piller V, Piller F, Eur J Biochem 2004 271 3623 3634 10.1111/j.1432-1033.2004.04284.x 15355339 (Pubitemid 39233604)
11. Clinical correlations of alpha2,6-sialyltransferase expression in colorectal cancer patients. Lise M, Belluco C, Perera SP, Patel R, Thomas P, Ganguly A, Hybridoma 2000 19 281 286 10.1089/027245700429828 11001400
12. Multiplex reverse transcription polymerase chain reaction assessment of sialyltransferase expression in human breast cancer. Recchi MA, Hebbar M, Hornez L, Harduin-Lepers A, Peyrat JP, Delannoy P, Cancer Res 1998 58 4066 4070 9751611 (Pubitemid 28440556)
13. ST6Gal-I expression in ovarian cancer cells promotes an invasive phenotype by altering integrin glycosylation and function. Christie DR, Shaikh FM, Lucas JA 4th, Lucas JA 3rd, Bellis SL, J Ovarian Res 2008 1 3 10.1186/1757-2215-1-3 19014651
14. Hypersialylation of beta1 integrins, observed in colon adenocarcinoma, may contribute to cancer progression by up-regulating cell motility. Seales EC, Jurado GA, Brunson BA, Wakefield JK, Frost AR, Bellis SL, Cancer Res 2005 65 4645 4652 10.1158/0008-5472.CAN-04-3117 15930282 (Pubitemid 40740800)
15. Tumor cell migration and invasion are regulated by expression of variant integrin glycoforms. Shaikh FM, Seales EC, Clem WC, Hennessy KM, Zhuo Y, Bellis SL, Exp Cell Res 2008 314 2941 2950 10.1016/j.yexcr.2008.07.021 18703050
16. CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Fukumori T, Takenaka Y, Yoshii T, Kim HR, Hogan V, Inohara H, Cancer Res 2003 63 8302 8311 14678989 (Pubitemid 37549482)
17. Sialylation of beta1 integrins blocks cell adhesion to galectin-3 and protects cells against galectin-3-induced apoptosis. Zhuo Y, Chammas R, Bellis SL, J Biol Chem 2008 283 22177 22185 10.1074/jbc.M8000015200 18676377
18. N- and O-glycans modulate galectin-1 binding, CD45 signaling, and T cell death. Earl LA, Bi S, Baum LG, J Biol Chem 2010 285 2232 2244 10.1074/jbc.M109.066191 19920154
19. ST6Gal-I regulates macrophage apoptosis via alpha2-6 sialylation of the TNFR1 death receptor. Liu Z, Swindall AF, Kesterson RA, Schoeb TR, Bullard DC, Bellis SL, J Biol Chem 2011 286 39654 39662 10.1074/jbc.M111.276063 21930713
20. Protein sialylation by sialyltransferase involves radiation resistance. Lee M, Lee HJ, Bae S, Lee YS, Mol Cancer Res 2008 6 1316 1325 10.1158/1541-7786.MCR-07-2209 18708363
21. Combination versus sequential cytotoxic chemotherapy in recurrent ovarian cancer: time for an evidence-based comparison. Markman M, Gynecol Oncol 2010 118 6 7 10.1016/j.ygyno.2010.03.017 20421127
22. Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin. Blair BG, Larson CA, Safaei R, Howell SB, Clin Cancer Res 2009 15 4312 4321 10.1158/1078-0432.CCR-09-0311 19509135
23. Glutathione induces cellular resistance against cationic dinuclear platinum anticancer drugs. Jansen BA, Brouwer J, Reedijk J, J Inorg Biochem 2002 89 197 202 10.1016/S0162-0134(02)00381-1 12062123 (Pubitemid 34327260)
24. BRCA1-IRIS overexpression promotes cisplatin resistance in ovarian cancer cells. Chock KL, Allison JM, Shimizu Y, ElShamy WM, Cancer Res 2010 70 8782 8791 10.1158/0008-5472.CAN-10-1352 20940403
25. Is cisplatin-induced cell death always produced by apoptosis? Gonzalez VM, Fuertes MA, Alonso C, Perez JM, Mol Pharmacol 2001 59 657 663 11259608 (Pubitemid 32273993)
26. Structure, recognition, and processing of cisplatin-DNA adducts. Jamieson ER, Lippard SJ, Chem Rev 1999 99 2467 2498 10.1021/cr980421n 11749487
27. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Landen CN Jr, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Mol Cancer Ther 2010 9 3186 3199 10.1158/1535-7163.MCT-10-0563 20889728
28. Altered mRNA expressions of sialyltransferases in ovarian cancers. Wang PH, Lee WL, Juang CM, Gynecol Oncol 2005 99 631 639 10.1016/j.ygyno.2005.07.016 16112178 (Pubitemid 41686547)
29. Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistant cancer cell lines. Liang XJ, Shen DW, Garfield S, Gottesman MM, Cancer Res 2003 63 5909 5916 14522917 (Pubitemid 37187492)
30. Alterations in the glycoform of cisplatin-resistant human carcinoma cells are caused by defects in the endoplasmic reticulum-associated degradation system. Nakagawa H, Ohira M, Hayashi S, Abe S, Saito S, Nagahori N, Cancer Lett 2008 270 295 301 10.1016/j.canlet.2008.05.019 18573595
31. Sialic acid changes in Dalton's lymphoma-bearing mice after cyclophosphamide and cisplatin treatment. Nicol BM, Prasad SB, Braz J Med Biol Res 2002 35 549 553 10.1590/S0100-879X2002000500006 12011939 (Pubitemid 34568223)
32. Differential binding of conA and WGA on the cell surface, the role of sialic acid in their expression and the increased activity of sialidase after cis-Platin treatment. Sodhi A, Prasad SB, Experientia 1985 41 93 95 10.1007/BF02005893 3917932 (Pubitemid 15163779)
33. Release of protein bound sialic acid from fibrosarcoma cells after cis-dichlorodiammine platinum (II) treatment: the possible role in tumor regression. Sarna S, Bhola RK, Sodhi A, Pol J Pharmacol Pharm 1988 40 295 302 3241769
34. Modulation of cytotoxicity of chemotherapeutic drugs by activated H-ras. Fan J, Banerjee D, Stambrook PJ, Bertino JR, Biochem Pharmacol 1997 53 1203 1209 10.1016/S0006-2952(97)00101-9 9175726 (Pubitemid 27224267)
35. Cisplatin resistance and oncogenes-a review. Dempke W, Voigt W, Grothey A, Hill BT, Schmoll HJ, Anticancer Drugs 2000 11 225 236 10.1097/00001813- 200004000-00001 10898536 (Pubitemid 30416950)
36. ST6Gal-I protein expression is upregulated in human epithelial tumors and correlates with stem cell markers in normal tissues and colon cancer cell lines. Swindall AF, Londono-Joshi AI, Schultz MJ, Fineberg N, Buchsbaum DJ, Bellis SL, Cancer Res 2013 73 2368 2378 10.1158/0008-5472.CAN-12-3424 23358684
37. Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. Micheau O, Solary E, Hammann A, Dimanche-Boitrel MT, J Biol Chem 1999 274 7987 7992 10.1074/jbc.274.12.7987 10075697 (Pubitemid 29144270)
38. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. Müller M, Strand S, Hug H, Heinemann EM, Walczak H, Hofmann WJ, J Clin Invest 1997 99 403 413 10.1172/JCI119174 9022073 (Pubitemid 27414797)
39. Cisplatin induces fas expression in esophageal cancer cell lines and enhanced cytotoxicity in combination with LAK cells. Matsuzaki I, Suzuki H, Kitamura M, Minamiya Y, Kawai H, Ogawa J, Oncology 2000 59 336 343 10.1159/000012192 11096347
40. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. Muller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M, J Exp Med 1998 188 2033 2045 10.1084/jem.188.11.2033 9841917 (Pubitemid 28562520)
41. Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity. Micheau O, Solary E, Hammann A, Martin F, Dimanche-Boitrel MT, J Natl Cancer Inst 1997 89 783 789 10.1093/jnci/89.11.783 9182976 (Pubitemid 27242279)
42. Induction of apoptosis in malignant pleural mesothelioma cells by activation of the Fas (Apo-1/CD95) death-signal pathway. Stewart JH 4th, Nguyen DM, Chen GA, Schrump DS, J Thorac Cardiovasc Surg 2002 123 295 302 10.1067/mtc.2002.119882 11828289 (Pubitemid 34127117)
43. Cisplatin augments cytotoxic T-lymphocyte-mediated antitumor immunity in poorly immunogenic murine lung cancer. Merritt RE, Mahtabifard A, Yamada RE, Crystal RG, Korst RJ, J Thorac Cardiovasc Surg 2003 126 1609 1617 10.1016/S0022-5223(03)00707-4 14666041 (Pubitemid 37449195)
44. Cisplatin-induced apoptosis involves membrane fluidification via inhibition of NHE1 in human colon cancer cells. Rebillard A, Tekpli X, Meurette O, Sergent O, LeMoigne-Muller G, Vernhet L, Cancer Res 2007 67 7865 7874 10.1158/0008-5472.CAN-07-0353 17699793 (Pubitemid 47281382)
45. Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. Lacour S, Hammann A, Grazide S, Lagadic-Gossmann D, Athias A, Sergent O, Cancer Res 2004 64 3593 3598 10.1158/0008-5472.CAN-03-2787 15150117 (Pubitemid 38657937)
46. Regulation of TNFR1 and CD95 signalling by receptor compartmentalization. Schutze S, Tchikov V, Schneider-Brachert W, Nat Rev Mol Cell Biol 2008 9 655 662 18545270 (Pubitemid 352032925)
47. Identification of genes that mediate sensitivity to cisplatin. Niedner H, Christen R, Lin X, Kondo A, Howell SB, Mol Pharmacol 2001 60 1153 1160 11723219 (Pubitemid 33144883)
48. The ABC of glycosylation. Perego P, Gatti L, Beretta GL, Nat Rev Cancer 2010 10 523 20574451
49. Increased levels and defective glycosylation of MRPs in ovarian carcinoma cells resistant to oxaliplatin. Beretta GL, Benedetti V, Cossa G, Biochem Pharmacol 2010 79 1108 1117 10.1016/j.bcp.2009.12.002 20005867
50. Quality control of human ABCG2 protein in the endoplasmic reticulum: ubiquitination and proteasomal degradation. Wakabayashi-Nakao K, Tamura A, Furukawa T, Nakagawa H, Ishikawa T, Adv Drug Deliv Rev 2009 61 66 72 10.1016/j.addr.2008.08.008 19111842